[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371776-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371776-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","progesterone-challenge-test-in-screening-of-endometrial-pathologic-lesions-in-high-risk-post-menopausal-women-abstract","Progesterone Challenge Test in Screening of Endometrial Pathologic Lesions in High-Risk Post-Menopausal Women - Abstract","","Objective: This study evaluates the prognostic value of the progesterone challenge test (PCT) for diagnosing hyperplastic and cancerous endometrium in high-risk postmenopausal women. Materials and methods: In a cross-sectional design, 72 postmenopausal women without abnormal uterine bleeding underwent PCT based on transvaginal ultrasound endometrial thickness of at least 4 mm. Bleeding within two weeks defined a positive test; all participants then received office endometrial biopsy for comparison. Results reported accuracy, sensitivity, specificity, PPV, and NPV.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/progesterone-challenge-test-in-screening-of-endometrial-pathologic-lesions-in-high-risk-post-menopausal-women-abstract/371776/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/progesterone-challenge-test-in-screening-of-endometrial-pathologic-lesions-in-high-risk-post-menopausal-women-abstract/371776.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the study on the progesterone challenge test (PCT)?","Question",{"text":63,"@type":64},"To evaluate the prognostic value of PCT for diagnosing hyperplastic and cancerous endometrium in high-risk postmenopausal women.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was a positive progesterone challenge test defined in this study?",{"text":68,"@type":64},"Women with endometrial thickness of 4 mm or more underwent PCT; bleeding (from spotting to severe bleeding) within the next two weeks was considered positive.",{"name":70,"@type":61,"acceptedAnswer":71},"Based on the study’s findings, is PCT suitable as a screening test for endometrial disease?",{"text":72,"@type":64},"No. The conclusion states that due to unacceptable sensitivity and specificity, PCT alone is not suitable for screening of endometrial cancer or hyperplasia.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371776,1790765070,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Original Article  \nProgesterone Challenge Test in Screening of Endometrial Pathologic Lesions in High-Risk Post-Menopausal Women  \nAfsaneh Tehranian; M.D.1, Hanieh Alambeygi; M.D.1, Sheida Abbasi; M.D.1, Akram Ghahghaei-Nezamabadi; M.D.1, Marjan Ghaemi; M.D.2, Rana Karimi; M.D.1  \n1 Department of Obstetrics and Gynecology, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran  \n2 Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran  \nReceived August 2024; Revised and accepted December 2024  \nAbstract  \nObjective: This study aimed to evaluate the prognostic value of the progesterone challenge test (PCT) in the diagnosis of hyperplastic and cancerous endometrium in high-risk postmenopausal women.  \nMaterials and methods: In this cross-sectional study, 72 postmenopausal women without abnormal uterine bleeding who had risk factors for endometrial cancer were recruited. Patients with endometrial thickness of 4 mm or more as determined transvaginal ultrasonography were tested with progesterone challenge test. If there were any bleeding (spotting to severe bleeding) in the next two weeks, the test would be considered positive. After two weeks, all of the participants despite the result of PCT underwent office endometrial biopsy. In the end, all the results of PCT were compared with endometrial biopsy results.  \nResults: The mean age of the participants was 57.7 ±8.15 years. The progesterone challenge test was positive in 17 women (22%) . Among the participants with positive progesterone challenge test, most of them show hyperplasia (62.5%) and 4.2% show endometrial cancer. According to the results, PCT had 37.5% accuracy, 20.8% sensitivity, 70.8 % specificity, 58.8% positive predictive value (PPV), and 30.9 % negative predictive value (NPV) for diagnosis of endometrial pathology.  \nConclusion: We suggest that due to the unacceptable sensitivity and specificity of the PCT, this test alone is not suitable for screening of endometrial cancer or hyperplasia.  \nKeywords: Progesterone Challenge Test; Endometrial Hyperplasia; Endometrial Cancer  \nIntroduction increasing all over the world (1) . The most important  \nEndometrial cancer is the most common gynecologic cancer in high-income countries and its incidence is  \nCorrespondence:  \nDr. Rana Karimi  \nEmail: [rkarimi@sina.tums.ac.ir](rkarimi@sina.tums.ac.ir)  \nrisk factor for endometrial cancer is unopposed estrogen exposure to the endometrium. The other risk factors such as obesity (2), diabetes (3), and the changes in fertility (for example increasing nulliparity) cause a rise in prevalence and number of deaths (1) .  \nIn Iran, the reports show a rise in the prevalence of endometrial cancer (4, 5) . According to comorbidity and risk factors, it seems necessary to use screening methods for early diagnosis and immediate decision for these women (6) .  \nThe most common symptom of endometrial cancer is usually abnormal uterine bleeding. Almost 90% of cancerous women, as the only symptom of disease, show bleeding or vaginal discharge (7) . In the diagnosis process of endometrial cancer or hyperplasia, the most challenging group is asymptomatic women. Approximately 10% of women diagnosed with endometrial cancer do not present with post-menopausal bleeding (8) .  \nOne of the nonaggressive methods which can be used for screening of endometrial pathologic lesions is transvaginal ultrasonography. Unfortunately inasymptomatic menopausal women transvaginal ultrasonography has not high accuracy in diagnosis (9).  \nYet there is no accurate, cost-benefit, and non-aggressive screening method for asymptomatic menopausal women. Routine biopsy is not acceptable as a screening method because it is aggressive and expensive. Routine ultrasonography is not a suitable test either in terms of diagnostic value or economic burden. On the other hand, early diagnosis of hyperplasia or even endometrial cancer in th","cbCaihCGg0XkIYNF","https://ap.wps.com/l/cbCaihCGg0XkIYNF","pdf",470048,"English","# Abstract\n## Objective\n## Materials and methods\n## Results\n## Conclusion\n# Introduction\n## Background and risk factors\n## Screening challenges\n## Progesterone challenge test rationale\n# Materials and methods\n## Study design and setting\n## Participants and inclusion criteria","[{\"question\":\"What was the main objective of the study on the progesterone challenge test (PCT)?\",\"answer\":\"To evaluate the prognostic value of PCT for diagnosing hyperplastic and cancerous endometrium in high-risk postmenopausal women.\"},{\"question\":\"How was a positive progesterone challenge test defined in this study?\",\"answer\":\"Women with endometrial thickness of 4 mm or more underwent PCT; bleeding (from spotting to severe bleeding) within the next two weeks was considered positive.\"},{\"question\":\"Based on the study’s findings, is PCT suitable as a screening test for endometrial disease?\",\"answer\":\"No. The conclusion states that due to unacceptable sensitivity and specificity, PCT alone is not suitable for screening of endometrial cancer or hyperplasia.\"}]","Progesterone Challenge Test in Screening of Endometrial Pathologic Lesions in High-Risk Post-Menopausal Women - Abstract | PDF",1790192840,13]